欧洲招标采购环境下男女共同接种HPV疫苗的成本效果分析
该模型评估了11个欧洲国家在招标采购价格下男女共同接种HPV疫苗相比仅女孩接种的成本效果。
要点
- 男女共同接种HPV疫苗在欧洲招标采购环境下很可能具有成本效果。
- 高接种率下需招标机制确保男孩接种仍具成本效果。
核心结论
- 在欧洲招标采购环境下,男女共同接种HPV疫苗具有经济吸引力。
- 招标机制需确保在高疫苗接种率下男孩接种仍具成本效果。
研究设计与样本
- 采用贝叶斯综合框架进行卫生经济学评价,覆盖11个欧洲国家(奥地利、比利时、克罗地亚、爱沙尼亚、意大利、拉脱维亚、荷兰、波兰、斯洛文尼亚、西班牙、瑞典)。
- 纳入各国关键流行病学和经济参数及当前HPV疫苗接种规划信息。
- 使用三个独立开发的HPV传播模型预测以定制区域特异性群体效应。
- 主要结局为比较男女共同接种与仅女孩接种的癌症预防例数和增量成本效果比(ICER),定义为每获得一个生命年的国际美元成本。
主要发现
- 在目前实现的疫苗接种率下,仅女孩接种可预防的癌症病例总数从克罗地亚每20万青春期前儿童队列(10万女孩加10万男孩)的318例(95%CI 197-405;9价疫苗覆盖率低于20%)到爱沙尼亚的1904例(95%CI 1741-2101;9价疫苗覆盖率低于70%)不等。
- 以同等覆盖率接种男孩,在克罗地亚增加168例(95%CI 121-213),在爱沙尼亚增加467例(95%CI 391-587)。
- 在统一的80%覆盖率下,大多数被调查国家(奥地利、比利时、意大利、拉脱维亚、荷兰、斯洛文尼亚、西班牙和瑞典)保持了有利的成本效果特征。
临床怎么用
- 在招标采购定价环境下,可考虑将男孩纳入HPV疫苗接种规划以提升成本效果。
- 需关注疫苗接种率水平,在高接种率下应通过招标机制确保男孩接种的经济性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In many European countries, human papillomavirus (HPV) vaccine uptake among girls has remained below target levels, supporting the scope for vaccination of boys. We aimed to investigate if sex-neutral HPV vaccination can be considered cost-effective compared with girls-only vaccination at uptake levels equal to those among girls and under tender-based vaccination costs achieved throughout Europe. METHODS: We investigated the cost-effectiveness of sex-neutral HPV vaccination in European tender-based settings. We applied a Bayesian synthesis framework for health economic evaluation to 11 countries (Austria, Belgium, Croatia, Estonia, Italy, Latvia, the Netherlands, Poland, Slovenia, Spain, and Sweden), accommodating country-specific information on key epidemiological and economic parameters, and on current HPV vaccination programmes. We used projections from three independently developed HPV transmission models to tailor region-specific herd effects. The main outcome measures in the comparison of sex-neutral with girls-only vaccination were cancer cases prevented and incremental cost-effectiveness ratios (ICERs), defined as the cost in international dollars (I$) per life-year gained. FINDINGS: The total number of cancer cases to be prevented by vaccinating girls at currently realised vaccine uptake varied from 318 (95% CI 197-405) per cohort of 200 000 preadolescents (100 000 girls plus 100 000 boys) in Croatia (under 20% uptake of the 9-valent vaccine) to 1904 (1741-2101) in Estonia (under 70% uptake of the 9-valent vaccine). Vaccinating boys at equal coverage increased these respective numbers by 168 (95% CI 121-213) in Croatia and 467 (391-587) in Estonia. Sex-neutral vaccination was likely to be cost-effective, with ICERs of sex-neutral compared with girls-only vaccination varying from I$4300 per life-year gained in Latvia (95% credibility interval 3450-5160; 40% uptake) to I$25 720 per life-year gained in Spain (21 380-30 330; 80% uptake). At uniform 80% uptake, a favourable cost-effectiveness profile was retained for most of the countries investigated (Austria, Belgium, Italy, Latvia, the Netherlands, Slovenia, Spain, and Sweden). INTERPRETATION: Sex-neutral HPV vaccination is economically attractive in European tender-based settings. However, tendering mechanisms need to ensure that vaccination of boys will remain cost-effective at high vaccine uptake rates. FUNDING: European Commission 7th Framework Programme and WHO.
引用
- Qendri V, Bogaards JA, Baussano I, et al. The cost-effectiveness profile of sex-neutral HPV immunisation in European tender-based settings: a model-based assessment. Lancet Public Health. 2020. PMID: 33120045. doi:10.1016/S2468-2667(20)30209-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。